<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04324307</url>
  </required_header>
  <id_info>
    <org_study_id>ChanghaiH-PP05</org_study_id>
    <nct_id>NCT04324307</nct_id>
  </id_info>
  <brief_title>Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer</brief_title>
  <official_title>Multicenter, Open-label Clinical Study of PD-L1/CTLA4 BsAb Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changhai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of PD-L1/CTLA4 BsAb for the second line treatment and the
      combination with chemotherapy for the first line treatment in pancreatic cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects who signed the informed consent were assigned to three cohorts according to the
      actual treatment status. Cohort 1 enrolled subjects receiving PD-L1/CTLA4 BsAb 5mg/kg iv Q2W
      for 2nd treatment; cohort 2 enrolled subjects receiving PD-L1/CTLA4 BsAb in combination with
      gemcitabine/albumin- paclitaxel as 1st treatment for 4-6 cycles with PD-L1/CTLA4 BsAb
      monotherapy maintainence; cohort 3 enrolled subjects received systemic chemotherapy,
      receiving PD-L1/CTLA4 BsAb combined with oxaliplatin / irinotecan / leucovorin / fluorouracil
      (FOLFIRINOX) as 1st treatment for 4-6 cycles withPD-L1/CTLA4 BsAb monotherapy maintainence;
      until disease progression according to RECIST 1.1, intolerable toxicity, withdrawal, death,
      2-yr treatment,who comes first.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 26, 2019</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>2 years</time_frame>
    <description>objective response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>2 years</time_frame>
    <description>Disease Control Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>2 years</time_frame>
    <description>Duration of Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTP</measure>
    <time_frame>2 years</time_frame>
    <description>Time to Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>2 years</time_frame>
    <description>Progression Free Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>2 years</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Locally Advanced and Metastatic Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>PD-L1/CTLA4 BsAb</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For 2nd line treatment，PD-L1/CTLA4 BsAb 5mg/kg Q2W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PD-L1/CTLA4 BsAb + GP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For 1st line treatment，PD-L1/CTLA4 BsAb 5mg/kg Q2W in combination with Gemcitabine 1000 mg/m2 and Nab-paclitaxel 125 mg/m2 , 28days/cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PD-L1/CTLA4 BsAb + FOLFIRINOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For 1st line treatment，PD-L1/CTLA4 BsAb 5mg/kg Q2W in combination with Oxaliplatin 68 or 85 mg/m2, Irinotecan 135 or 150 or 180 mg/m2, Calcium Folate 400 mg/m2, Fluorouracil 2400mg/m2, 14 days/cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-L1/CTLA4 BsAb</intervention_name>
    <description>PD-L1/CTLA4 BsAb 5mg/kg, iv，Q2W</description>
    <arm_group_label>PD-L1/CTLA4 BsAb</arm_group_label>
    <arm_group_label>PD-L1/CTLA4 BsAb + FOLFIRINOX</arm_group_label>
    <arm_group_label>PD-L1/CTLA4 BsAb + GP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>GP</intervention_name>
    <description>Gemcitabine 1000mg/m2, iv, D1,8,15, 28days/cycle; nab-Paclitaxel 125mg/m2，iv，D1,8,15, 28days/cycle;</description>
    <arm_group_label>PD-L1/CTLA4 BsAb + GP</arm_group_label>
    <other_name>Gemcitabine</other_name>
    <other_name>nab-Paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>FOLFIRINOX</intervention_name>
    <description>Fluorouracil 2400mg/m2，iv，D1, 14days/cycle; Oxaliplatin 68-85mg/m2，iv, D1,14days/cycle;Irinotecan135-180mg/m2，iv, D1, 14days/cycle;Calcium Folate 400mg/m2，iv, D1, 14days/cycle;</description>
    <arm_group_label>PD-L1/CTLA4 BsAb + FOLFIRINOX</arm_group_label>
    <other_name>Oxaliplatin</other_name>
    <other_name>Irinotecan</other_name>
    <other_name>Calcium Folate</other_name>
    <other_name>Fluorouracil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histology or cytology confirmed as pancreatic ductal adenocarcinoma;

          -  ECOG 0-1;

          -  adequate organ function (absolute neutrophil count ≥1.5 x 109/L; platelet count ≥100 x
             109/L; creatinine &lt; 1.5 x ULN (upper normal) or calculated creatinine clearance (
             CRCI) ≥ 60mL/min; albumin ≥ 30g/L; total bilirubin &lt;1.5 x ULN; aspartate
             aminotransferase (AST) &lt; 2.5 x ULN; alanine aminotransferase (ALT) &lt; 2.5x ULN; INR or
             PT &lt; 1.5x ULN, and aPTT &lt;1.5x ULN);

          -  no obvious symptoms of jaundice and ascites;

          -  no other serious underlying diseases

        Exclusion Criteria:

          -  patients with active brain metastases;

          -  history of autoimmune diseases, or need to be treated with corticosteroids and
             immunosuppressive agents;

          -  past history of unstable angina, symptomatic congestive heart failure, severe
             arrhythmia, myocardial infarction within 6 months, QT interval prolongation (&gt;450ms);

          -  other malignant tumors within the last 5 years;

          -  pregnant or lactating women;

          -  NRS ≥ 4 points;

          -  unintentional weight loss ≥ 5% within 1 month before the first dose even if peripheral
             or central vein nutrition support,
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gang Jin, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changhai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shiwei Guo, Doctor</last_name>
    <phone>86-18621500666</phone>
    <email>gestwa@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Suizhi Gao, Doctor</last_name>
    <phone>86-13167137990</phone>
    <email>gaosuizhi@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Changhai hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shiwei Guo, Doctor</last_name>
      <phone>86-18621500666</phone>
      <email>gestwa@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 25, 2020</study_first_submitted>
  <study_first_submitted_qc>March 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2020</study_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changhai Hospital</investigator_affiliation>
    <investigator_full_name>Guo ShiWei</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Folfirinox</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

